Chapter 6 · Book Chapter
Paid Access Peer Reviewed

Theranostics in Nuclear Medicine

Diya1, Mayank Maithani1,*, Sahil Singh Thakur1, Gargi1

Corresponding author: [email protected]

Abstract

Theranostics is the use of one molecular target for both diagnosis and therapy: a radiopharmaceutical carrying an imaging radionuclide first shows where the target is expressed, and a closely matched radiopharmaceutical carrying a therapeutic radionuclide then delivers a cytotoxic radiation dose to the same sites. The working motto of the discipline, “see what you treat, treat what you see”, states the logic in six words: the image is no longer only a description of disease but the selection test for treatment and, afterwards, the record of where the radiation went. This chapter traces the historical development from radioiodine to radioligand therapy, the theranostic pair concept, the construct of a theranostic radiopharmaceutical, the radiation physics of therapeutic emissions, the radionuclides used, clinical applications, patient selection, protocol and administration, dosimetry principles, and the role of the radiographer and nuclear medicine technologist.

TheranosticsNuclear medicineRadioligand therapyTheranostic pairRadiopharmaceuticalsDosimetryLutetium-177Targeted radionuclide therapy

Author Affiliations

  • 1 Scholar, Saraswati College of Pharmacy, SGC Group, Gharuan 140413, Mohali, Punjab, India.

How to Cite this Chapter

Diya, Maithani, M., Thakur, S. S., & Gargi (2026). Theranostics in Nuclear Medicine. In S. S. Gusain, A. Thakur, Anmol, J. Prajapati, A. Sharma, P. Thakur, & P. Kaundal (Eds.), Advances in Radiology and Medical Imaging (pp. 60–72). WiseLeaf Scientific Ventures. https://doi.org/10.66079/wiseleaf.advances-radiology-medical-imaging.2026
Back to the full volume

Related WiseLeaf titles